Shopping Cart
Remove All
Your shopping cart is currently empty
Vatelizumab is a humanised monoclonal antibody targeting Integrin α2β1 (very late antigen 2, VLA-2, CD49b), which enhances the frequency of regulatory T cells via the p38 MAPK signalling pathway and can be used for research into multiple sclerosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,570 | - | In Stock | |
| 25 mg | $2,330 | - | In Stock | |
| 50 mg | $3,130 | - | In Stock |
| Description | Vatelizumab is a humanised monoclonal antibody targeting Integrin α2β1 (very late antigen 2, VLA-2, CD49b), which enhances the frequency of regulatory T cells via the p38 MAPK signalling pathway and can be used for research into multiple sclerosis. |
| Synonyms | TMC-2003, SAR 339658, GBR500, GBR 500, CHR-1103, CHR1103 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 1238217-55-4 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.